Cost-Effectiveness of Cardiac Resynchronization Therapy for Heart Failure

Kaltrina Bajraktari's systematic review synthesizes evidence on the cost-effectiveness of cardiac resynchronization therapy (CRT) for heart failure. The review, last updated in May 2026, includes 18 studies published between 2004 and 2025, reporting incremental cost-effectiveness ratios (ICERs) for CRT treatments. The data is available as a 15.9 KB DOCX file under a CC-BY-4.0 license.

Use Cases

• Benchmarking cost-effectiveness ratios for CRT devices based on reported ICER values.
• Comparing economic outcomes of CRT-P versus CRT-D therapies based on the review's findings.
• Informing health policy decisions on high-value interventions for heart failure based on synthesized evidence.

Strengths

• Includes 18 studies meeting specific inclusion criteria for a systematic review.
• Reports specific ICER ranges (e.g., €3,048-€71,447/QALY for CRT+OMT) converted to a common 2024 euro currency.
• Systematic search was conducted across three major databases (Web of Science, PubMed, Scopus) and registered in PROSPERO.

Limitations

• The dataset is a 15.9 KB document, indicating a very limited scope of raw data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare, author Kaltrina Bajraktari.

Collection Method

Systematic review of literature from Web of Science, PubMed, and Scopus.

Time Range

Studies published from January 2004 up to July 2025.

Freshness

Last updated 2026-05-21 12:55:05; freshness should be verified.

Geography

Global evidence, with costs assessed against country-specific thresholds.